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PURPOSE. Ripasudil (Glanatec), a selective Rho-associated coiled coil-containing protein kinase
(ROCK) inhibitor, was approved in Japan in September 2014 for the treatment of glaucoma
and ocular hypertension. The purpose of this study was to investigate the effect of ripasudil
eye drops on corneal endothelial morphology, as ROCK signaling is known to modulate the
actin cytoskeleton.
METHODS. Morphological changes in the corneal endothelium were evaluated in human
subjects by specular and slit-lamp microscopy, following topical administration of ripasudil.
We also used a rabbit model to evaluate the effect of ripasudil on clinical parameters of the
corneal endothelium. Twenty-four hours after ripasudil application, corneal specimens were
evaluated by phalloidin staining, immunohistochemical analysis, and electron microscopy.
RESULTS. Specular microscopy revealed morphological changes in human eyes, and slit-lamp
microscopy showed guttae-like findings. The rabbit model showed morphological changes
similar to those seen in human eyes after ripasudil administration. Electron microscopy
demonstrated that these alterations are due to the formation of protrusions along the cell–cell
borders, but this formation is transient. Expression of corneal endothelial function-related
markers was not disrupted; corneal thickness and corneal volume were not changed; and no
cell death was observed following ripasudil administration.
CONCLUSIONS. Ripasudil induces transient guttae-like findings in humans, most likely due to
protrusion formation along intracellular borders caused by the reduction in actomyosin
contractility of the corneal endothelial cells. No severe adverse effects were observed.
Physicians should be aware that ROCK inhibitors can cause these guttae-like findings, to avoid
misdiagnosing patients as having Fuchs endothelial corneal dystrophy. (www.umin.ac.jp/ctr
number, UMIN000018340.)
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Glaucoma, a progressive optic neuropathy, causes visualfield loss and is one of the major causes of secondary
blindness.1,2 Research confirms that the progression of visual
field loss due to glaucomatous optic neuropathy is suppressed
by reducing intraocular pressure (IOP); consequently, the main
goal of glaucoma treatment is to reduce IOP.3,4 A number of
pharmaceutical agents, such as prostaglandin analogues, b-
blockers, carbonic anhydrase inhibitors, and a2-agonists, are
used in clinical settings, but IOP is not well controlled by the
currently available drugs in a certain number of patients.4
Development of new therapeutic agents therefore remains
eagerly anticipated.
Rho-associated coiled coil-containing protein kinase (ROCK)
inhibitors and other drugs that modulate the actin cytoskeleton
are reported to reduce IOP by promoting aqueous humor
outflow through the trabecular meshwork.5–12 A selective
ROCK inhibitor, Y-27632, altered the distribution of actin stress
fibers and cell-substrate adhesion of cultured trabecular
meshwork and Schlemm’s canal cells.8,10,13 Topical administra-
tion of ROCK inhibitor eye drops also reduced IOP in rabbit and
monkey models by increasing the outflow capacity,8,14 a
unique mechanism among conventional IOP-lowering
drugs.8,9,15 In addition, a clinical study demonstrated that the
ROCK inhibitors SNJ-1656 (Y-39983)16,17 and AR-1228618
reduced IOP in healthy volunteers, as well as in patients with
glaucoma and ocular hypertension.
Ripasudil (GLANATEC), a selective ROCK inhibitor, was
approved in Japan in September 2014 for the treatment of
glaucoma and ocular hypertension.15 Ripasudil exhibited IOP-
lowering effects in rabbits and monkeys,19 and phase 1 clinical
trials showed that ripasudil reduced IOP in healthy adult
volunteers.20 In addition, randomized clinical studies showed
that 0.4% ripasudil reduced IOP in patients with primary open-
angle glaucoma and ocular hypertension.21
Wato et al.22 observed morphological changes in the corneal
endothelium by noncontact specular microscopy following
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instillation of ripasudil in cynomolgus monkeys; however, the
reasons for these changes are not yet well elucidated. The
corneal endothelium is a nonregenerative tissue, and severe
damage can cause vision loss due to corneal edema.23
Therefore, further investigation is required to evaluate this
effect of ripasudil eye drops on the corneal endothelium. The
aim of the current study was to perform a pathological
investigation of corneal endothelial cells (CECs) to elucidate
how ripasudil administration induces the observed morpho-
logical changes in the corneal endothelium.
MATERIALS AND METHODS
Ethics Statement
Animals were housed and treated in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. The rabbit experiments were performed at Doshisha
University (Kyoto, Japan), according to the protocol approved
by that university’s Animal Care and Use Committee (Approval
No. 0831). The human data were obtained in accordance with
the tenets set forth in the Declaration of Helsinki.
Ripasudil Administration in Human Subjects
The effect of ripasudil eye drops (GLANATEC ophthalmic
solution 0.4%; Kowa Company, Ltd., Nagoya, Japan) on
corneal endothelium was examined in two human subjects
(46-year-old female and 38-year-old male) who had no corneal
diseases. Each was administered one drop of ripasudil to the
right eye, and the corneal endothelium was observed by
noncontact specular microscopy and slit-lamp microscopy at
specific time points: before administration and 1, 3, 6, and 24
hours after a single dose of ripasudil. This study was
performed according to a protocol approved by the Institu-
tional Review Board of Doshisha University. Clinical trial
registration was obtained from UMIN UMIN000018340
(http://www.umin.ac.jp/english/).
Ripasudil Administration in a Rabbit Model
A single dose of ripasudil was administered into the right eyes
of nine rabbits. Anterior segments and corneal endothelium
were evaluated by slit-lamp microscopy and contact specular
microscope (Konan scanning slit specular microscope; Konan
Medical, Nishinomiya, Japan) for 24 hours. Corneal thickness,
FIGURE 1. Pseudo guttae-like morphological changes in human corneal endothelium induced by ripasudil eye drops. (A) Noncontact specular
microscopy image and slit-lamp photograph of a healthy subject administered one drop of 0.4% ripasudil. (B) Slit-lamp photograph demonstrating
pseudo guttae of healthy subject 1 hour after topical administration of 0.4% ripasudil.
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corneal volume, and corneal refractive power were evaluated
with a Pentacam (OCULUS Optikgera¨te GmbH, Wetzlar,
Germany). Intraocular pressure was determined with a
Tonovet (icare Finland, Vantaa, Finland) (n ¼ 5). Corneal
specimens obtained from four rabbits were used for analysis by
scanning electron microscopy and transmission electron
microscopy. For repeated-dose administration, ripasudil was
administered into the right eye of three rabbits twice daily for 7
days, and the corneal endothelium was evaluated by contact
specular microscopy and histological analysis.
Fluorescent Staining
Rabbit corneal specimens were fixed in 4% formaldehyde and
incubated for 30 minutes at room temperature in 1% bovine
serum albumin (BSA) to block nonspecific binding. The actin
fibers were evaluated by examining the corneas after actin
staining with a 1:400 dilution of Alexa Fluor 488-conjugated
phalloidin (Life Technologies Corp., Carlsbad, CA, USA). The
effect on function-related proteins was investigated by
immunohistochemical analyses of ZO-1, N-cadherin, and Naþ/
Kþ-ATPase using primary antibodies against Zona Occludens 1
(ZO-1; 1:200; Zymed Laboratories, South San Francisco, CA,
USA), N-cadherin (1:200, Zymed Laboratories), and Naþ/Kþ-
ATPase (1:200; Upstate Biotechnology, Lake Placid, NY, USA).
Alexa Fluor 488-conjugated goat anti-mouse (Life Technologies
Corp.) was used as a secondary antibody at a 1:1000 dilution.
The effect of ripasudil on cell death was examined in
corneas obtained from five rabbits 24 hours after administra-
tion of ripasudil. The specimens were stained with annexin V
and propidium iodide (PI) by incubating with annexin V–
fluorescein isothiocyanate (FITC; 1:200; Zymed Laboratories)
and PI (1:200, Zymed Laboratories) for 30 minutes at 378C,
followed by fixation in 4% formaldehyde. As a positive control,
10 lM staurosporine was injected into anterior chamber in two
rabbits and corneas were recovered after 24 hours. Nuclei
were stained with 4’,6-diamidino-2-phenylindole (DAPI) (Vec-
tor Laboratories, Burlingame, CA, USA). The slides were
examined with a fluorescence microscope (TCS SP2 AOBS;
Leica Microsystems, Wetzlar, Germany).
Scanning Electron Microscopy
The effect of ripasudil on corneal endothelial morphology was
evaluated in corneal specimens obtained from four rabbits at 1,
3, and 24 hours after a single dose of ripasudil or control.
Excised corneas were fixed in 2.5% glutaraldehyde and 2%
paraformaldehyde in 0.1 M So¨rensen buffer (pH 7.2–7.4) for at
least 3 hours at room temperature. The samples were washed
in the buffer, postfixed with 1% aqueous osmium tetroxide,
dehydrated through an ascending ethanol series, and trans-
ferred to hexamethyldisilazane (HMDS) (Agar Scientific,
Stansted, UK), which was allowed to sublimate off. The
samples were mounted on stubs, sputter-coated with gold, and
examined by scanning electron microscopy (model 5600; JEOL
Ltd., Tokyo, Japan).
Transmission Electron Microscopy
Corneal specimens were obtained from four rabbits at 1, 3, and
24 hours after a single dose of ripasudil or control. The samples
were washed in 0.1 M So¨rensen buffer, fixed with 2.5%
glutaraldehyde and 2% paraformaldehyde in 0.1 M So¨rensen
buffer, and postfixed with 1% osmium tetroxide. After
dehydration in an ascending ethanol series and acetone, the
samples were infiltrated and embedded in epoxy resin.
Ultrathin sections were collected on uncoated copper grids
and double stained with uranyl acetate and lead. Sections were
FIGURE 2. Slit-lamp microscopy, contact specular microscopy, and
histological evaluation of rabbit corneal endothelium after single-dose
administration of ripasudil eye drops. (A) 0.4% ripasudil was
administered topically as an eye drop in five rabbits, followed by slit-
lamp microscopy evaluation. (B) Endothelial morphology was evalu-
ated by contact specular microscopy after administration of 0.4%
ripasudil. Representative images obtained from five independent
rabbits are shown. (C) Corneas recovered from five rabbits 24 hours
after administration of 0.4% ripasudil were stained with phalloidin.
Expression of the function-related proteins ZO-1, N-cadherin, and Naþ/
Kþ-ATPase was also evaluated by immunofluorescence staining. Nuclei
were stained with DAPI. Scale bar: 50 lm. (D) To evaluate the effect of
ripasudil, corneas from five rabbits recovered 24 hours after
administration of 0.4% ripasudil were stained with annexin V and PI.
Staurosporine was injected into the anterior chamber to induce
apoptosis as a positive control. Nuclei were stained with DAPI. Scale
bar: 50 lm.
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examined with a transmission electron microscope (JEM-
1400Plus; JEOL Ltd.) equipped with a charge-coupled device
camera.
Statistical Analysis
The Student’s t-test was used to determine statistical signifi-
cance (P value) of differences between mean values of the two-
sample comparison. Results are expressed as mean 6 SEM.
RESULTS
Effect of Ripasudil Eye Drops on Corneal
Endothelium in Human Subjects
Noncontact specular microscopy demonstrated an indistinct
cell border after 1 hour. The cell border was still slightly
indistinct after 3 hours and was distinct once again by 6 hours;
no pathological changes, such as distinct cell borders and cell
loss, were observed at 24 hours after administration (Fig. 1A).
Conjunctival injection, which was previously reported as a
possible adverse effect of ROCK inhibitors, was observed
coincident to the morphological changes in the corneal
endothelium at 3 hours (Fig. 1A). A guttae-like appearance of
the cornea was observed by slit-lamp microscopy after 1 to 3
hours of treatment, but this resolved within 24 hours (Fig. 1B).
These changes were observed similarly in both human
subjects.
Effect of Ripasudil Eye Drops on Rabbit Corneal
Endothelium
A histological analysis of corneal endothelium following
treatment with ripasudil was conducted on a rabbit model.
Slit-lamp microscopy showed no severe adverse corneal effects
such as corneal edema, but contact specular microscopy
showed that the cell border of the corneal endothelium
became indistinct by 30 minutes to 1 hour after dosing (Figs.
2A, 2B). Similar to the finding in human subjects, it recovered
within 3 to 6 hours, and no morphological changes or cell
losses were observed 24 hours after administration. At 24
hours after administration, the expression of the function-
related proteins ZO-1 (tight junction), N-cadherin (adherence
junction), and Naþ/Kþ-ATPase (pump function) was well
preserved in the normal phenotypes (Fig. 2C). Annexin V
and PI staining showed no induction of apoptosis or cell death
by ripasudil administration (Fig. 2D). Ripasudil administration
twice daily for 7 days in the rabbit model caused no
FIGURE 4. Morphological evaluation of rabbit corneal endothelium
after treatment with ripasudil eye drops. (A) 0.4% ripasudil was
topically administered to the rabbit eye, and 1 hour after treatment the
cornea and control cornea were recovered. Actin fibers were stained
by phalloidin. Scale bar: 50 lm. (B) Corneas were recovered from
rabbits 1, 3, and 24 hours after administering a single dose of 0.4%
ripasudil. Rabbit corneal endothelium was evaluated by scanning
electron microscopy. Images were representative of two independent
rabbits for every time point. Scale bar : 10 lm.
FIGURE 3. The effect of repeated-dose administration of 0.4% ripasudil
on rabbit corneal endothelium. (A) For repeated-dose administration,
0.4% ripasudil was administered twice daily for 7 days in three rabbits,
and the corneal endothelium was examined by contact specular
microscopy. (B) To evaluate cell morphology, the corneal endothelium
was stained with phalloidin. Annexin V and PI staining was performed
to evaluate the effect of ripasudil on corneal endothelial cell death.
Nuclei were stained with DAPI. Scale bar: 50 lm.
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morphological changes, as determined by contact specular
microscopy (Fig. 3A) and phalloidin staining (Fig. 3B). In
addition, no annexin V- and PI-positive cells were observed
(Fig. 3B).
The ROCK inhibitors regulate the actin cytoskeleton, so we
next examined the expression pattern of actin in the corneal
endothelium. Phalloidin staining revealed a distribution of actin
fibers at the cell cortex in both ripasudil-treated and control
eyes, and no obvious differences were observed 24 hours after
administration (Fig. 4A). However, scanning electron micros-
copy demonstrated the formation of protrusions along the cell
borders, which recovered by 3 hours (Fig. 4B). Transmission
electron microscopy also revealed the formation of protrusions
at the cell border of the corneal endothelium, which also
reverted to the control level within 24 hours (Fig. 5A). Tight
junctions, adherence junctions, and gap junctions were
present, even at 1 hour when specular microscopy revealed
indistinct cell borders, and retention of adhesion on Desce-
met’s membrane was unchanged (Fig. 5B). Organelles such as
mitochondria and endoplasmic reticulum were unaltered
morphologically by ripasudil administration throughout the
24-hour study.
FIGURE 5. Transmission electron microscopy of rabbit corneal endothelium after treatment with ripasudil eye drops. (A, B) Corneas administered
ripasudil were recovered after 1, 3, and 24 hours. Rabbit corneal endothelium was then evaluated by transmission electron microscopy. Images are
representative of two independent rabbits for every time point. J, intact junctional complexes (tight junction and adherens junction); GJ, gap
junction; M, mitochondria; ER, endoplasmic reticulum. Scale bars: 5 lm (A); 1 lm (B).
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We next evaluated the clinical parameters in the rabbit
model that undergo changes if corneal endothelial function is
damaged. Corneal endothelial cell density, determined by
contact specular microscopy, was not decreased by ripasudil
(Fig. 6A). Corneal thickness and corneal volume, which are
maintained by the barrier and pump functions of the corneal
endothelium, were not significantly changed by ripasudil (Figs.
6B, 6C). The lack of any significant changes in refractive power
also demonstrated that corneal shape was preserved, despite
the formation of protrusions at the cell border (Fig. 6D). The
IOP was significantly lower at 1 and 3 hours after treatment,
showing the effect of ripasudil against glaucoma (Fig. 6E).
DISCUSSION
The ROCK isoforms ROCK1 and ROCK2 were originally
discovered as a target of the small Guanosine-5’-triphosphate
(GTP)-binding protein RhoA.24 The Rho-binding domain within
the coiled-coil region of ROCK was identified, but subsequent
FIGURE 6. Evaluation of rabbit clinical parameters after treatment with ripasudil eye drops. (A) 0.4% ripasudil was administered topically as an eye
drop in the right eyes of five rabbits, and corneal endothelial cell density was evaluated by contact specular microscopy after 24 hours. (B) Corneal
thickness of rabbit after ripasudil administration was evaluated with an ultrasound pachymeter. (C, D) The effect of ripasudil on corneal volume and
refractive power was evaluated by Pentacam. (E) Intraocular pressure of rabbits was measured by Tonovet after treatment with 0.4% ripasudil. *P <
0.01.
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research revealed that several molecules activate or inhibit
ROCK via multiple contact points.25–28 ROCK mediates various
important cellular functions, such as cell shape, motility,
adhesion, and proliferation.24 Active Rho-GTP binds to ROCK
and increases the phosphorylation of a number of downstream
target proteins, such as myosin light chain (MLC), Lin-11/Isl-1/
Mec-3 kinase (LIMK), and MLC phosphatase complex of type 1
(MYPT1). This is followed by stabilization of filamentous actin
and an increase in the actin–myosin contractile force.24,29
ROCK has attracted the interest of researchers as a potential
therapeutic target for various diseases, such as cancer,
neuronal degenerative disease, asthma, cardiovascular disease,
and hypertension, as well as glaucoma.28,30 In fact, fasudil was
approved in Japan and China for the treatment of cerebral
vasospasm in 1995.28 To our knowledge, ripasudil is the first
approved ROCK inhibitor eye drop for the treatment of
glaucoma and ocular hypertension.15
Ripasudil is anticipated to alter cytoskeletal contraction of
the trabecular meshwork and Schlemm’s canal cells to increase
outflow of aqueous humor15,16,19; therefore, several types of
ocular cells can be affected. For instance, the high occurrence
of hyperemia is a common symptom after topical administra-
tion of ROCK inhibitors.14,16,18 Coincidently, slight to mild
conjunctival hyperemia was observed in more than half of the
participants in ripasudil clinical trials.20,21 This hyperemia is
thought to arise because of conjunctival vessel dilation due to
alteration of vascular endothelial cells.16 However, the
hyperemia was transient, and no conjunctival hemorrhage,
which occurred in animal experiments,14 was observed in the
clinical studies, suggesting the safety of ripasudil eye drops.31
In this study, we showed that ripasudil eye drops caused
morphological changes in the corneal endothelium as observed
by noncontact specular microscopy. Of importance, this
change was also recognized as guttae-like findings by slit-lamp
microscopy. Guttae are collagenous excrescences of the
corneal endothelial basement membrane (Descemet’s mem-
brane) and are observed in as many as 5% of the population
aged over 40.32 They are also typical features of Fuchs
endothelial corneal dystrophy.33 To avoid misdiagnosing a
patient as having Fuchs endothelial corneal dystrophy,
physicians should be aware that guttae-like findings can be
caused by ROCK inhibitor eye drops.
We investigated these guttae-like findings further using the
rabbit model and demonstrated that they are induced by the
formation of mild protrusions along the cell–cell borders.
Protrusion formation is considered an effect of ripasudil,
because ROCK inhibitors modulate the actin cytoskeleton in
various types of cells. We have also reported that ROCK
inhibitors alter the cell morphology of cultured CECs.34 A
pharmacodynamics study revealed that ripasudil has high
intraocular permeability and that it penetrates into all eye
tissues except the lens,19 suggesting that ripasudil affects the
corneal endothelium. Tian and his colleagues7 reported that
intracameral infusion of H-7 to monkey eyes induced
morphological change in the corneal endothelium, observed
by specular microscopy, and membrane ruffling along the
intracellular borders, as observed by SEM.7 H-7 is a serine-
threonine kinase inhibitor that inhibits actomyosin contractil-
ity and eventually produces cellular relaxation.5–7,35 Taken
together, alteration of corneal endothelium borders by
ripasudil and other actin cytoskeleton-modulating drugs is
suggested to be a common feature of these drugs.
The corneal endothelium is essential for maintaining
corneal clarity via its barrier function that suppresses the
overflow of aqueous humor into the corneal stroma. Trans-
mission electron microscopy demonstrated that tight junc-
tions, adherence junctions, and gap junctions were present 1
hour after ripasudil administration, and the corneal thickness
and volume were unchanged. This suggests that the barrier
function of the corneal endothelium was not disrupted. ROCK
inhibitors can change the localization of junctional proteins
and increase the permeability of Schlemm’s canal,11 but this
difference may be explained by the fact that the effects of
ROCK inhibitors depend on the cell types.28 One remaining
question is the effect of long-term use of ripasudil eye drops on
the corneal endothelium in clinical settings. We have shown
that morphological changes are transient in this animal model,
but careful evaluation in human patients is needed.
In conclusion, we have demonstrated that ripasudil induces
transient guttae-like findings in humans, most likely due to
protrusion formation along intracellular borders caused by the
reduction in actomyosin contractility of the CECs. Physicians
should appreciate that ROCK inhibitors can cause these guttae-
like findings in order to avoid misdiagnosing patients as having
Fuchs endothelial corneal dystrophy.
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